Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>Introducing the CEO. Shaun Bagai has spent his career in medtech, starting as an intern at TransVascular. Guided by the company’s CEO, he chose entrepreneurship over medical school to make a broader impact on patient care. </li><li>Bagai stayed at TransVascular to manage clinical research and, following its acquisition by Medtronic (NYSE: MDT), gained firsthand experience in bringing medical devices to market.</li><li>He later deepened his expertise in developing and commercializing disruptive technologies through roles at Ardian (also acquired by Medtronic) and HeartFlow (NASDAQ: HTFL). I</li></ul>

Introducing the CEO. Shaun Bagai has spent his career in medtech, starting as an intern at TransVascular. Guided by the company’s CEO, he chose entrepreneurship over medical school to make a broader impact on patient care. Bagai stayed at TransVascular to manage clinical research and, following its acquisition by Medtronic (NYSE: MDT), gained firsthand experience in bringing medical devices to market.He later deepened his expertise in developing and commercializing disruptive technologies through roles at Ardian (also acquired by Medtronic) and HeartFlow (NASDAQ: HTFL). I

RenovoRx's Differentiated Targeted Drug Delivery Platform Addresses Hypovascular Cancers

RenovoRx Inc

RenovoRx's Differentiated Targeted Drug Delivery Platform Addresses Hypovascular Cancers